

Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer

Shanbeh Zienolddiny
Vidar Skaug

Section for Toxicology and Biological
Work Environment, National Institute
of Occupational Health, Oslo, Norway

Abstract: Lung cancer is a major public health problem throughout the world. Among the most frequent cancer types (prostate, breast, colorectal, stomach, lung), lung cancer is the leading cause of cancer-related deaths worldwide. Among the two major subtypes of small cell lung cancer and nonsmall cell lung cancer (NSCLC), 85% of tumors belong to the NSCLC histological types. Small cell lung cancer is associated with the shortest survival time. Although tobacco smoking has been recognized as the major risk factor for lung cancer, there is a great interindividual and interethnic difference in risk of developing lung cancer given exposure to similar environmental and lifestyle factors. This may indicate that in addition to chemical and environmental factors, genetic variations in the genome may contribute to risk modification. A common type of genetic variation in the genome, known as single nucleotide polymorphism, has been found to be associated with susceptibility to lung cancer. Interestingly, many of these polymorphisms are found in the genes that regulate major pathways of carcinogen metabolism (cytochrome P450 genes), detoxification (glutathione *S*-transferases), adduct removal (DNA repair genes), cell growth/apoptosis (TP53/MDM2), the immune system (cytokines/chemokines), and membrane receptors (nicotinic acetylcholine and dopaminergic receptors). Some of these polymorphisms have been shown to alter the level of mRNA, and protein structure and function. In addition to being susceptibility markers, several of these polymorphisms are emerging to be important for response to chemotherapy/radiotherapy and survival of patients. Therefore, it is hypothesized that single nucleotide polymorphisms will be valuable genetic markers in individual-based prognosis and therapy in future. Here we will review some of the most important single nucleotide polymorphisms in the metabolic pathways that may modulate susceptibility, prognosis, and therapy in NSCLC.

Keywords: lung cancer, susceptibility, polymorphism, single nucleotide polymorphism, non-small cell lung cancer

Introduction

Cancer is a major public health problem throughout the world and is the third most common disease after cardiovascular and communicable diseases. According to 2011 health statistics published by the World Health Organization, 7.6 million deaths (13% of all deaths) were due to cancer in 2008, and it is estimated that this number will rise to 11 million deaths by 2030.¹ The latest figures from United States Cancer Statistics indicate that there will be 1.6 million new cancer cases in 2011 in the US alone, of which 0.6 million are estimated to die from the disease.²

Among the most frequent cancer types observed globally (prostate, breast, colorectal, stomach, skin, lung) lung cancer is the one which kills the greatest number of patients. According to recent surveys published by United States Cancer Statistics, lung cancer

Correspondence: Shanbeh Zienolddiny
National Institute of Occupational Health,
Pb 8149 Dep, N-0033 Oslo, Norway
Tel +47 2319 5100
Fax +47 2319 5204
Email shan.zienolddiny@stami.no

is the leading cause of cancer death in the United States.³ Establishment of national cancer registries and efforts by the International Agency for Research on Cancer have led to improved cancer statistics nationally and globally. Data from national cancer registries and the International Agency for Research on Cancer have helped to determine accurately the etiological factors for lung cancer and to design national prevention strategies based on knowledge of specific risk factors in each region or country. Furthermore, data on ethnic differences in risk of acquiring lung cancer are becoming available for many countries with multiethnic populations.^{4,5} These data indicate that in addition to external risk factors, genetic factors may also contribute to variations in risk of developing lung cancer. Specifically, normal genetic variations at the DNA level, known as single nucleotide polymorphisms (SNPs) may contribute greatly to the understanding of both interindividual and interpopulation differences, given exposure to similar environmental and lifestyle factors.^{6,7} A large number of genetic polymorphisms have been identified as candidate biomarkers for lung cancer. Many of these polymorphisms have been replicated and validated by the International Lung Cancer Consortium which has a database of lung cancer containing thousands of lung cancer cases and controls from populations in Asia, Europe, and the Americas.

Single nucleotide polymorphisms

The genome of living organisms contains multiple types of structural genetic variations (variation in chromosome number, DNA fragment variations, copy number variations) and molecular levels (base modifications, nucleotide substitutions). An SNP is a common type of variation in the DNA sequence which occurs in greater than one percent of the population. As shown in Figure 1, individuals in a population may inherit these base variations from their parents so that they may be homozygous or heterozygous for an SNP at a specific site of the genome. The number of SNPs has been estimated to be 1/100 nucleotide, totaling about 3×10^7 in a diploid human genome. Many of these SNPs are located within the regulatory regions of the genes which may influence the expression of the gene and some others are located within the exons or exon-intron boundaries which may modify the protein function or the splicing sites, respectively. The biological consequences of SNPs are shown in Figure 2.

Polymorphisms in major biological pathways for lung carcinogenesis

Many of the polymorphisms are found in the genetic pathways controlling enzymes involved in the metabolism

and detoxification of tobacco smoke carcinogens, repair of harmful DNA adducts, and suppression of mutations induced by the carcinogens.⁸ Many of them are also present in the genes regulating the immune system and cellular stress responses. The functional significance of a few of these polymorphisms has been elucidated. However, since it is hypothesized that an SNP may occur in approximately every 100 nucleotides, many more remain undiscovered. In the following sections, we will focus on a selection of polymorphisms for which there is evidence of association with lung cancer risk and finally we will address some prognostic and therapeutic aspects derived from these data.

Polymorphisms in genes involved in biotransformation of carcinogens

It has been known for a long time that there are individual differences in the metabolism, detoxification, and removal of carcinogens from the body.^{6,9} The cytochrome P450 (CYP450) system is the biological pathway to deal with metabolism of chemical carcinogens and synthetic drugs that enter the body.^{10,11} In the human genome, CYP450 is comprised of 115 genes, of which 57 code for bioactive enzymes whereas the remainder are considered to be pseudogenes.¹²

Tobacco smoke is thought to contain more than 4000 chemicals, of which more than 60 are carcinogens, with polycyclic aromatic hydrocarbons (PAHs) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNKs) as the major groups.¹² PAHs are biotransformed by CYP450




Figure 1 Normal genetic variation in DNA bases. Single nucleotide polymorphisms are normal nucleotide variations inherited from parents. There is a common C allele at a specific site of a gene whereas some individuals carry a variant allele T at that specific site. The individuals in the population will have three genotypes. Person 1 has inherited a C allele from mother (*M*) at that specific site whereas a C allele from the father (*P*). Therefore, this person is a C/C homozygote for this specific site. Person 2 has a maternal C and a paternal T and is heterozygote while person 3 carries two variant alleles T (inheriting a maternal T allele and a paternal T allele) at this site and is therefore a “variant homozygote” in the population.




Figure 2 Types of single nucleotide polymorphisms (SNPs) and their biological consequences. SNPs occurring in the coding sequences (exons) may lead to codon change leading to an amino acid (AA) or no AA change. Changes in AA could lead to either change in protein structure or function. Noncoding regulatory SNPs could potentially lead to changes in transcription, mRNA stability, protein structure or function, or changes in binding sites of miRNA.

enzymes to epoxides which are then converted by epoxide hydrolase to diol-epoxides that may bind to DNA, forming PAH-DNA adducts. Benzo(a)pyrene is a typical PAH, which is mainly bioactivated to B(a)P-7,8 dihydro-epoxide by CYP4501A1 (CYP1A1) and CYP450 1B1 (CYP1B1). Subsequent hydrolyzation of B(a)P-7,8 dihydro-epoxide by microsomal epoxide hydrolase (EPHX1) and another round of metabolism by CYP1B1, the ultimate carcinogen benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide, is formed, which is highly mutagenic.¹⁴ CYP1A1 and CYP1B1 are found overexpressed in lung cancer.¹⁵ Both enzymes are induced by tobacco smoke and their induction may affect the level of PAH-DNA adducts in cells.¹⁶ An almost four-fold higher expression of the *CYP1A1* gene was found in current female smokers¹⁷ and there was a positive correlation between PAH-DNA adducts with *CYP1A1* expression in the lung, which may partly explain gender differences in susceptibility to NSCLC.^{18,19} Higher expression of CYP3A5, another CYP enzyme involved in biotransformation of PAHs, has also been reported to correlate with higher adduct levels in bronchoalveolar macrophages in smokers.²⁰ The *CYP1A2* gene is also an important *CYP* gene which is closely linked to *CYP1A1* and may affect carcinogen metabolism, but its expression has not been investigated.²¹ The NNKs found in tobacco are also linked to the risk of lung cancer. NNK is biotransformed by CYP2A6, and the enzyme is also involved in the metabolism of nicotine, which may affect smoking behavior and addiction.²²

The extent of induction of *CYP450* genes in the liver and lung varies between smokers in the population, and may be due to the presence of functional polymorphisms in these genes.^{23,24} Several SNPs in the *CYP* genes have been associated with the risk of nonsmall cell lung cancer (NSCLC), but only a few of these have been confirmed in multiple studies to be of functional importance. MspI and Ile462Val polymorphisms in the *CYP1A1* gene have been studied in relation to lung cancer in many populations. A recent meta-analysis of 71 studies including all ethnic groups has concluded that both polymorphisms may be associated with an increased risk of lung cancer, with odds ratios of 1.19 (95% confidence interval [CI] 1.11–1.28) for MspI and 1.20 (95% CI 1.08–1.33) for Ile462Val.²⁵ However, in a subgroup analysis by ethnicity, significantly increased risks were found for the MspI and Ile462Val polymorphisms among East Asians. No associations were found with Ile462Val, and only marginal significant associations were detected for the MspI polymorphism in Caucasians.

Several polymorphisms in the *CYP1B1* have been found to be associated with risk of NSCLC.^{26–28} A meta-analysis including results from 10 studies involving more than 16,000 subjects concluded that *CYP1B1* SNPs Leu432Val (rs1056836), Ala119Ser (rs1056827), Arg48Gly (rs10012), and Asn453Ser (rs1800440) were associated with risk for lung cancer.²⁷ The data suggested that homozygote carriers of the variant 432Val/Val polymorphism had 40% higher risk of lung cancer, whereas the Val allele alone was associated with a 26% increased risk. Individuals with 119Ser/Ser genotype

compared with 119 Ala/Ala had a two-fold increased risk of lung cancer, whereas for the individuals with the 48Gly/Gly genotype, the risk was four-fold compared with carriers of the wild-type 48 Arg/Arg genotype. The Asn453Ser polymorphism was only associated with risk in women.

Although functional data on risk-associated polymorphisms are mostly lacking, some *in vivo* and *in vitro* results support higher gene expression and enzymatic activity for the variant alleles of *CYP1B1*.^{29–31} Furthermore, some of the genetic variants in the *CYP1B1* gene have been found to affect survival and anticancer drug therapy in NSCLC patients.^{32,33}

The glutathione *S*-transferases (GSTs) and *N*-acetyltransferases (NATs) are involved in conjugation and detoxification of reactive metabolites produced by CYP enzymes. The GSTM1, GSTT1, GSTP1, and glutathione peroxidases are the most important members of the phase II enzymes, all of which are polymorphic.³⁴ The aryl and heterocyclic amines are metabolized by NAT1 and NAT2 enzymes that act via *N*- and *O*-acetylation reactions. Polymorphisms in the *NAT* genes result in variants of fast, slow, or intermediate acetylator phenotypes in humans.³⁵ We and others have found significant associations between polymorphisms in several of these genes and risk of NSCLC.³⁶ For example, the *GSTT* Met139Ile and *GSTP1* Ala114Val substitutions were significantly associated with NSCLC risk. There are multiple studies showing evidence of risk of lung cancer associated with the NAT1 fast acetylator phenotype.^{36,37} For some genes, such as Ala222-Val in methylenetetrahydrofolate reductase (*MTHFR*), the associations with NSCLC risk are not consistent, although functional analysis of this polymorphism has shown that the Val allele may result in lower enzyme activity, lower folate levels, and lower methylation levels.^{38,39}

In addition to PAHs and NNKs, reactive oxygen/nitrogen species in tobacco smoke may contribute to lung carcinogenesis. Reactive oxygen/nitrogen species are detoxified by a number of antioxidant enzymes, including microsomal EPHX1, myeloperoxidase, catechol-*O*-methyltransferase (COMT), and manganese superoxide dismutase. Several functional polymorphisms in these genes have been identified, which may affect gene expression or enzyme activities.^{40,41} His139 Arg polymorphism in the *EPHX1* gene, the Val16 Ala in the *SOD2* gene, and Val158Met in the *COMT* gene have been found to modify lung cancer risk.^{36,42}

Polymorphisms in DNA repair genes

Cells are exposed to thousands of DNA lesions resulting from exposure to endogenous and exogenous carcinogenic agents.⁴³

If unrepaired, this large number of lesions could lead to global genomic instability in the form of chromosome aberrations, mutations, and DNA rearrangements, which are commonly found in most cancer cells. To avoid genomic instability, cells have evolved damage-specific DNA repair pathways that are tightly regulated and orchestrated in normal cells.⁴⁴ A reduced or diminished capacity to repair DNA lesions predisposes individuals to an increased susceptibility to cancer. Individuals with lung cancer have been shown to have a lower DNA repair capacity.⁴⁵ However, reduced DNA repair capacity in patients may be beneficial for therapy with alkylating agents which act by inducing damage to the DNA of tumor cells.

There are at least five major DNA repair pathways, each dealing with specific DNA damage, with some proteins having overlapping or backup functions.⁴³ Bulky DNA damage (ie, PAH adducts) are mainly repaired via nucleotide excision repair pathway, which consists of more than 30 proteins involved in various steps of damage recognition, DNA incision/opening, DNA synthesis, and ligation.⁴⁶ The nucleotide excision repair genes mostly studied in relation to cancer are xeroderma pigmentosum (XP) also known as “excision repair cross complementing” (ERCC) where XPA, XPC, ERCC1, ERCC2/XPD, ERCC4/XPF, and *ERCC5/XPG* are key enzymes.^{47,48} Another DNA repair mechanism that deals with large strand breaks such as double-strand breaks is DNA double-strand break repair, which involves homologous and nonhomologous recombinational end-joining repair pathways, including several protein families such as the RAD51, ataxia telangiectasia-mutated, and x-ray repair cross complementing (XRCC) proteins.^{49,50}

Presence of reactive oxygen/nitrogen species may lead to formation of 7,8-dihydro-8-oxoguanine (8-oxo-G), apurinic/aprimidinic (AP) sites and single-strand breaks in DNA. These lesions are repaired by the base-excision repair pathway.^{51,52} 8-oxo-G is a major form of DNA damage that mispairs with thymine, leading to mutations (G to T transversion). 8-oxo-G is excised from DNA by the 8-oxoguanine glycosylase-1 (OGG1) protein. The enzymatic activity of OGG1 creates an AP site which is then repaired by the AP endonuclease-1 (APEX/APE1) enzyme.⁵³ Complete repair of diverse DNA damage requires activity of many other proteins, including the x-ray repair cross complementation-1 (XRCC1), methylpurine glycosylase, polymerase B, ligase-3, exonuclease-1, and proliferating cell nuclear antigen.⁵⁴ The base-excision repair pathway has been considered to be important in sensitization to radiotherapy of lung tumors.⁵⁵

The alkylating agents in tobacco smoke lead to addition of various methyl and alkyl groups to the DNA bases. Among others, the O6-methylguanine (O6-meG) is a major adduct that may mispair with thymine during replication, resulting in G to A mutations. O6-meG is removed from DNA by the suicidal O6-meG-DNA methyltransferase protein in human cells. This protein has been shown to have an important role in the response of patients treated with DNA-alkylating drugs.^{56,57}

A recent meta-analysis including results from 241 associations has confirmed that polymorphisms in the DNA repair genes, *APEX/APE*, *XRCC1*, *ERCC1*, *ERCC2*, *ERCC5*, *NBN*, *XPA*, *POLI*, *MGMT*, and *OGG1* could affect the risk of lung cancer.⁵⁸ A follow-up study of this meta-analysis has found strong cumulative evidence for an association between polymorphisms in the *ERCC2* gene and lung cancer risk.⁵⁹ It is interesting to note that polymorphisms in the *ERCC1* and *ERCC2* genes have also been found to modulate survival and response to drugs used in therapy for NSCLC.⁶⁰ A newly published prospective study from a Texas population has also confirmed the association between SNPs in the *XRCC4* gene and lung cancer risk.⁶¹

We and others have also found polymorphisms in double-strand break repair genes to modulate lung cancer susceptibility.^{62–64} An almost three-fold increased risk of lung cancer was found for the *XRCC-2* Arg188His and homozygote group compared with subjects with the Arg188 Arg genotype.⁶⁴ Mutation or deletion of the amino acid at this site of *XRCC-2* protein reduces cell survival following DNA damage. In a case-control study, we found that the Thr297Ile polymorphism in exon 7 of the *XRCC9/FANCG* gene was associated with a reduced risk of NSCLC where only 0.3% of lung cancer cases carried variant genotypes compared with 2.5% of controls.⁶⁴ It was also found that the *ATR* Thr211Met SNP was associated with a decreased risk of NSCLC. *ATR* (ataxia telangiectasia and Rad3-related) protein plays a central role in phosphorylation of DNA damage-sensing proteins, such as the ataxia telangiectasia-mutated protein and TP53. The target proteins are phosphorylated by *ATR* protein in response to double-strand breaks, reactive oxygen/nitrogen species, hypoxia, and inflammation. It has been shown that drugs such as gefitinib may sensitize NSCLC tumors to radiotherapy via inhibition of the ataxia telangiectasia-mutated pathway.⁶⁵

Polymorphisms in the TP53 pathway

TP53 is a tumor suppressor protein and is activated to prevent carcinogenic effects of DNA damage. Activation of TP53 induces cell cycle arrest, allowing DNA repair

machinery to repair damage.^{66,67} Cells with unreparable DNA damage are removed by apoptosis, which is also induced by TP53. The importance of this protein is supported by the fact that the *TP53* gene is mutated in more than half of NSCLC tumors, and that mutation of the gene is an early event in lung carcinogenesis.⁶⁸ The murine double minute 2 (*MDM2*, also called *HDM2*), plays a central role in regulation of TP53 activities through its ubiquitin ligase activity leading to rapid degradation of TP53 protein. Furthermore, TP53 induces transcription of the *MDM2* gene, generating an autoregulatory feedback loop.⁶⁹ Overexpression of *MDM2* protein has also been observed in lung tumors, which may indicate a complementary mechanism to TP53 inactivation.⁷⁰

Polymorphisms in the *TP53* and *MDM2* genes have been reported to affect cancer risk.⁷¹ The most functional SNPs in this pathway are those located in exon 4 of the *TP53* gene (Arg72Pro) and SNP T309G in promoter of the *MDM2* gene.^{67,72} Our laboratory has shown that lung cancer patients carrying the Pro72 allele may have a lower frequency of *TP53* mutations in tumors.⁷³ The 72Pro allele has been suggested to lead to higher transcription of DNA repair genes than the Arg72 allele.⁷⁴ In contrast, the Arg72 variant has been associated with greater apoptotic potential. The T309G SNP located at position 309 in the first intron of the *MDM2* gene has been thoroughly investigated, both in association studies and in functional experiments. This T to G substitution was shown to lead to higher transcription of the gene.⁷² Our study of SNP309 indicated that the G/G genotype was more frequently found among NSCLC cases than in healthy controls.⁷⁵ Interestingly, the strongest effect of SNP309 polymorphism was seen among women, suggesting that the effect of overexpression of *MDM2* caused by SNP309 may be enhanced by sex hormones, as proposed by Bond et al.⁶⁷ Some studies have shown the SNP309 to be associated with lower age at diagnosis but our results indicated different roles of SNP309 depending on the *TP53* status in the tumors. In lung cancer patients with tumors having mutations in the *TP53* gene, the G allele was associated with older age at diagnosis. Conversely, no such effect of age was seen in cases without mutations in *TP53*. Although few studies have not found SNP309 to be associated with a risk of NSCLC,^{76,77} arguing that ethnic differences may exist, most of the recently published meta-analyses have found the GG genotype of SNP309 to be associated with a 12%–27% increased risk of lung cancer.^{78,79} Furthermore, an interaction between Arg72Pro polymorphism of *TP53* and SNP309 of *MDM2* has been proposed.⁸⁰ It has also been shown that both of these polymorphisms may affect clinical outcome in NSCLC.^{81,82}

The cysteine-dependent aspartate-specific proteases (CASPs) are also important in apoptotic cell signaling. The CASP8 is a key enzyme in this pathway and a six nucleotide insertion-deletion polymorphism (–652 6N ins/del, rs3834129) in the *CASP8* gene promoter was found to be associated with susceptibility to lung cancer although not all studies are consistent.⁸³ In our study, we found that only men with homozygote del/del genotypes had an increased risk of NSCLC, and that the risk was only elevated in patients with a nonmutated *TP53* gene.⁸⁴

Polymorphisms in inflammatory genes

Inflammation has been recognized as a factor contributing to the pathogenesis of many cancers where chronic inflammation, arising as a result of continuous exposure to tobacco components, may result in an excess of oxidative stress and contribute to tumor promotion and progression in the lung.^{85,86} Epidemiological studies have shown an increased risk of lung cancer in patients with inflammatory airway phenotypes, such as chronic obstructive pulmonary disease, emphysema, bronchitis, and asthma.⁸⁷ The components of cigarette smoke stimulate epithelial and immune cells to overproduce proinflammatory proteins, including interleukins 1-beta (IL-1 β), IL-6, IL-8, tumor necrosis factor alpha (TNF- α), and cyclo-oxygenase-2 (COX-2, also known as prostaglandin-endoperoxide synthase 2). Increased levels of these proteins have been observed in NSCLC tumors.⁸⁸ Moreover, upregulation of the COX-2 protein has been associated with poorer survival in NSCLC in some studies,^{89,90} whereas others have not found such a correlation.^{91,92} Due to overexpression of COX-2 in tumors, several clinical trials have been designed to investigate the chemopreventive effect of nonsteroidal anti-inflammatory drugs, of which COX-2 is a major target, particularly in smokers.^{93–95} Furthermore, it has been observed that the main mechanism of action of drugs such as carboxyamidotriazole may be through inhibition of proinflammatory cytokines.⁹⁶ In several studies, we and others have shown that polymorphisms in some of the inflammation genes may predispose individuals to NSCLC.^{97–100}

IL-1 β is a central proinflammatory cytokine important in initiating and balancing the level of inflammatory response. In several epidemiological and molecular biological studies we have investigated SNPs in the *IL-1B* gene in relation to NSCLC and expression of this gene in the lung. We have found statistically significant effects on NSCLC in association with the T-31C, T-3893 G,

and –1464 G regulatory SNPs.^{100,101} Haplotype analyses of the risk SNPs showed that G-3893 A, G-1464C, C-511T, and T-31C SNPs formed a specific haplotype in NSCLC cases but not in controls.¹⁰¹ It was also found that this haplotype was associated with higher *IL-1B* expression in the lung. In further molecular studies, we focused on the T-31C SNP since the C allele of the SNP disrupted the TATA-box and was thus believed to affect transcription. Indeed, the experimental data from our laboratory showed that the *IL-1B* promoter with T in this position had higher transcriptional activity compared with the C-SNP.¹⁰² On the other hand, the C-SNP created a novel binding site for transcription factor YY1, which can regulate transcription either as an activator or repressor.¹⁰³ In addition, it was observed that the polymorphisms could affect mutations in the *TP53* gene in tumors.^{100,101}

The *IL-6* G-174C SNP was associated with a risk of developing squamous cell carcinoma of the lung.⁹⁷ This SNP, which is located in the promoter of the *IL-6* gene, has been shown to be associated with increased IL-6 and C-reactive protein levels and a decline in lung function in patients with chronic obstructive pulmonary disease.^{104,105} Indeed, IL-6 has been found to be the predominant cytokine expressed by tumor-associated lymphocytes and macrophages in lung tumors.⁹⁶ Our data suggested a decreased risk of NSCLC associated with the T-251A SNP of the *IL-8* gene in female subjects only, which may partly support gender differences in lung cancer risk. A recent meta-analysis has confirmed the role of *IL8* T-251A polymorphism as a susceptibility marker for lung cancer.¹⁰⁶ This *IL-8* gene promoter SNP has also been reported to affect *IL-8* gene expression.¹⁰⁷

The cytokine TNF- α is known to influence the pathogenesis of cancer, and several polymorphisms of this gene, such as G-308 A and G488 A, have been suggested to be associated with susceptibility to lung cancer.¹⁰⁸ Other polymorphisms in the TNF- α pathway have also been associated with the risk of NSCLC.¹⁰⁹ In our case-control study, a moderate association between risk of NSCLC and the *TNF- α* G488A polymorphism was found.¹¹⁰ Furthermore, it was found that a combination of three out of four polymorphisms in the genes *Casp8*, *IL10*, *MMP1*, and *Seps1* was associated with a four-fold increase in the risk of NSCLC.¹¹⁰

A polymorphism in the 3-UTR region of the *COX-2* gene (COX–2.8473) may be associated with an increased risk of NSCLC whereas other polymorphisms have not shown associations.^{97,111} The COX-2 8473 SNP has been suggested to alter stability of the COX-2 mRNA levels, although there are no specific functional data.

Polymorphisms in nicotinic acetylcholine and dopaminergic receptors

Genome-wide association studies have recently reported that polymorphisms at chromosome 5p15.33 (*TERT-CLPTMIL*), 6p21.33, and 15q25.1 (*CHRNA3-CHRNA5*) loci influence the risk of developing lung cancer.^{112,113} We also found an increased and dose-dependent association with risk of NSCLC associated with the studied variants, consistent with previously published data.²⁶ Additionally, our results provided evidence that individuals carrying these SNPs accumulated higher levels of smoking-related DNA adducts in the lung. There is also some evidence that polymorphisms at 15q25.1 that harbor the nicotinic acetylcholine receptor genes, *CHRNA3* and *CHRNA5*, may be related to smoking behavior in smokers.^{114–116} The SNP at 5p15.13 (rs402710) maps within intron 4 of the cleft lip and palate transmembrane 1-like (*CLPTMIL*) gene which is upregulated in cisplatin-resistant (CDDP) ovarian tumor cell lines and its overexpression has been shown to induce apoptosis in CDDP-sensitive cells.¹¹⁷

Dopamine receptors have been identified both in human lung cancer cell lines and in the normal lung. It is known that there is great individual variation in activity of the dopaminergic system.^{118,119} We studied 11 SNPs in the *DRD2*, *DRD4*, and *DAT1/SLC6A3* genes encoding dopamine receptor or transporter molecules in relation to lung cancer susceptibility. We found that carriers of the *DRD2*-141Cdel, G3208T, TaqIB_G > A, *DRD4* C-521T, and *SLC6A3/DAT1* C-1476A had an increased risk of NSCLC.¹²⁰ It was also found that the G allele of *DRD2*-1412A > G had a protective effect.

Individual predisposition to lung cancer prognosis and consequences for therapy

Epidemiological studies reveal poor overall survival for patients with lung cancer, with only a slight improvement in recent years.^{121,122} Mean age-adjusted relative 5-year survival was found to be 12% in the Eurocare database, but there are wide variations between countries.¹²³ Such differences may be due in part to sociodemographic factors, delays in diagnosis, and different therapeutic regimes. Recent data on patient cancer survival from the Nordic cancer registries showed no differences in survival rates in the Nordic countries 3–5 years after diagnosis.¹²⁴ However, when analyzing survival, irrespective of the follow-up period, shorter life expectancy was registered in Denmark, possibly related to unfavorable stage distribution. The staging of lung cancer at the time of

diagnosis reflects the size and grade of the tumor and also the extent of spread from the primary tumor, thus staging is an essential predictor for survival. According to a Surveillance, Epidemiology, and End Results (SEER) report, the 5-year relative survival by stage for lung cancer patients treated in the United States during 2001–2007 was as follows (stage distribution in parentheses): localized tumors (confined to primary site) (15%): 52.0%, regional (spread to local lymph nodes) (22%): 24.2% distant (with metastasis: (56%)/3.6%, and unknown (untagged) (7%): 8.1.

Other predictors of prognosis have shown inconsistent results across studies and within stages at the time of diagnosis. Young age at diagnosis indicates greater survival compared with elderly patients,^{125–129} although not in all studies.¹³⁰ Elderly patients present more comorbidity and are generally treated less with primary surgery than younger lung cancer patients.¹³¹ Females have better survival^{132–134} but this is not consistent across all studies.¹³⁵ Also histological subtypes may influence outcome to some extent, but the results are inconsistent. The largest progress on survival in recent years, related to therapy has been shown to be for adenocarcinoma, as shown in the data from the SEER Cancer Statistics Review, 1975–2008.¹²¹ In these SEER data, the one-year survival rate in patients with adenocarcinoma histology increased from 15% to 23%, mainly in the 2002–2005 period in which erlotinib, gefitinib, and pemetrexed were approved.¹³⁶

Individual susceptibility accounts for additional variation in prognosis within the various prognostic groups that have been under study. Such differences have been shown for an increasing number of polymorphisms in cancer-related genes, although staging is the most important predictive factor for prognosis.¹²⁶ Even with the introduction of targeted agents and the establishment of multiple lines of therapy, median survival for patients with advanced NSCLC does not considerably extend beyond 1 year. Genetic susceptibility factors are nevertheless crucial for continuous new research and development towards targeted therapy for individual lung cancer patients.

In a systematic review of 90 studies on genetic polymorphisms and lung cancer outcomes published between 1990 and 2009, 170 genetic variants were reported in relation to overall survival and toxicity. The most frequently studied were polymorphisms in the carcinogen metabolism/biotransformation, DNA repair, TP53/MDM2, and inflammation pathways, some of which are reviewed here. Heterogeneity in study populations, incomplete reporting of important population or study characteristics, inadequate power, and inconsistencies in methodology were common.

Large-scale confirmatory studies on individual polymorphisms are generally not found.¹³⁷

High susceptibility to smoking-related lung cancer has been associated with polymorphisms of the *CYP1A1* gene. The recent meta-analysis of 71 studies demonstrated that the MspI and Ile462Val polymorphism of the *CYP1A1* gene is a risk factor for lung cancer susceptibility, and that these associations vary in different ethnic populations.²⁵ Lung cancer patients from Turkey showed no polymorphisms in *CYP450* genes that were important for prognosis.¹³⁸ Individuals with a susceptible *CYP1A1* genotype have been found to be at higher risk when the genotype is combined with a deficient *GSTM1* genotype¹³⁹ and other risk factors such as *p16* promoter hypermethylation, DAPK, and RAR beta in smokers with null *GSTM1*,¹⁴⁰ as well as *EGFR* polymorphism and its treatment with EGFR tyrosine kinase inhibitors.¹⁴¹ The polymorphisms *CYP2D6**4 (C188T), *CYP3A1**3 (G-44 A), and *CYP3A5**3 were found to be associated with response to vinorelbine in a small (n = 59) Chinese lung cancer patient group.¹⁴²

Functional polymorphisms in DNA repair genes may interact with chemotherapy and reduce the treatment effect. Cisplatin is a commonly used adjuvant chemotherapeutic agent which acts by cross-linking DNA strands, thus inhibiting DNA replication and disfavoring apoptosis of tumor cells. DNA repair enzymes that counteract these effects may diminish the chemotherapeutic effect. Enhanced activity in the nucleotide excision repair pathway may thus unintentionally confer platinum resistance, through enhanced recognition, removal, and resynthesis of DNA. Lung cancer patients with loss of expression of the ERCC1 protein (by immunohistochemistry) showed improved survival during cisplatin treatment, compared with patients expressing ERCC1 in their tumors. In the case of nonadjuvant therapy, subjects expressing ERCC1 had increased survival compared with patients with abolished expression in their tumors.⁶⁰ This indicates a beneficial effect when it comes to adjuvant cisplatin therapy. In a recent systematic review of *ERCC1* gene polymorphisms in patients with advanced stages of NSCLC, the sensitivity of platinum-based chemotherapy was significantly associated with polymorphism of *ERCC1* C1181T, but not with *ERCC2/XPD* Asp312 Asn and Lys751Gln polymorphisms.¹⁴³ Improved survival for patients harboring the *ERCC1* C1181T has been shown by others^{144,145} in a recent study which also included the C8092A polymorphism with similar improved prognosis when treated with platinum-based chemotherapy.¹⁴⁶ The *ERCC1* C8092A polymorphism has been shown to be effective for adjuvant platinum therapy

in a Japanese population independently of ERCC1 protein expression¹⁴⁷ and the variant allele has also been proven as a prognostic marker when adjuvant chemotherapy was given to lung cancer patients in Greece and Spain.^{148,149} In a Chinese population, among two functional variants in the *ERCC1* 5'-flanking region, -433T > C and -262G > T, which cooperatively influence transcriptional regulation of *ERCC1*, the 262G allele was associated with better drug response and longer survival time compared with the 262T allele.¹⁵⁰ Patients with the *XRCC7* 399 Arg/Arg and *ERCC1* 8092CA genotypes are susceptible to treatment with gefitinib.¹⁵¹ Other variant alleles in the DNA repair pathways are also sensitive when lung cancer patients are treated with chemotherapeutic agents other than platinum.^{147,152,153}

The *TP53* pathway, involving *TP53*, *MDM2*, *MDM4*, and *P73* among others, mediates cellular stress responses inducing DNA repair, cell-cycle arrest, senescence, and apoptosis. These effects enhance the ability to suppress tumor formation and to respond to targeted cancer therapy. Mutations in *TP53* gene in tumors are in most studies related to shortened survival of patients.¹⁵⁴ Most clinical studies suggest that NSCLC patients with TP53 alterations have a worse prognosis and may be relatively more resistant to chemotherapy and radiation.⁶⁸ The Arg72Pro polymorphism in *TP53* has been shown to be associated with high-grade NSCLC and significantly shorter survival.¹⁵⁵ Additionally, there are data that support prognostic effects of intron 3 polymorphism of *TP53* gene that may result in a significantly poorer prognosis in NSCLC.¹⁵⁵

The MDM2 SNP309 was associated with MDM2 transcripts, mRNA levels, and survival in stage I NSCLC patients with wild-type *TP53* gene in the tumors,¹⁵⁶ whereas this SNP was not shown to be a predictive marker for survival in other studies.¹⁵⁷

In stage III–IV NSCLC patients on platinum-based chemotherapy, the combined effect of multiple biologically relevant functional polymorphisms in the *TP53* pathway genes *TP53* Arg72Pro, *P73* G4C14-to-A4T14, and *MDM2* T309G had a higher impact on shortening survival when combined, in a gene-dose-dependent manner, compared with each single polymorphism.¹⁵⁸ Other polymorphisms in the TP53 pathway may also be related to prognosis, such as the Arg allele of the p21 WAF1/CIP1 codon 31, which is a downstream target of TP53.¹⁵⁹ The combined effect of *TP53* with another tumor suppressor gene, *PTEN*, has been shown to decrease survival rates in NSCLC, thus identifying a subgroup of patients with particularly aggressive disease.^{68,160}

Somatic mutations in the *EGFR* tyrosine kinase domain have been demonstrated as being essential for the treatment of NSCLC.¹⁶¹ Polymorphisms in the *EGFR* (rs373506, rs759165, and rs6958497) were shown to be independent candidate biomarkers to predict NSCLC survival in a Chinese population.¹⁶² However, there are great interethnic differences¹⁶³ and the findings are not consistent, due to differences in study design and analysis.¹⁶⁴ Functional *EGFR* germ line polymorphisms may confer a risk for *EGFR* somatic mutations in NSCLC with a predominant effect on exon 19 micro deletions.¹⁶⁵

Polymorphisms in the genes involved in the pulmonary inflammatory response may be tightly linked to the carcinogenic process. NSCLC patients with the *CRP* 1846T/T genotype in the C-reactive protein (*CRP*) gene showed a poorer prognosis.¹⁶⁶ Furthermore, polymorphisms in the *COX-2* gene associated with reduced overall survival of NSCLC patients has been shown.¹⁶⁷ A functional polymorphism of the innate immunity gene *MBL2* has also been associated with lung cancer survival among white patients.¹⁶⁸ Polymorphisms in inflammatory genes have been shown to increase the risk of inflammatory side effects in NSCLC patients treated with radiation or chemoradiation. Among 37 inflammation-related genes in 173 patients with stage III disease, 59 SNPs were profiled. Increased risk for esophagitis was observed for nine SNPs of *COX-2* variants, ie, rs20417 (hazards ratio [HR] 1.93, 95% CI 1.10–3.39), rs5275 (HR 1.58, 95% CI 1.09–2.27), and rs689470 (HR 3.38, 95% CI 1.09–10.49). Polymorphisms in the proinflammatory genes *IL-1A* (rs1800587), *IL-8* (rs4073), *TNF- α* (rs1799724), *TNFRSF1B* (rs1061622), and *MIF* (rs7555622), were related to increased risk for pneumonitis, whereas a polymorphism in the *NOS-3* gene (rs1799983) displayed a protective effect with a 45% reduction in pneumonitis risk (HR 0.55, 95% CI 0.31–0.96). The risk of pneumonitis was also modulated by polymorphisms in anti-inflammatory genes, including genetic variation in *IL13* (rs20541 and rs180925) each associated with increased risk (HR 2.95, 95% CI 1.14–7.63 and HR 3.23, 95% CI 1.03–10.18, respectively).¹⁶⁹

MicroRNAs (miRNAs) are novel regulators of gene expression that are linked to the main oncogene networks, including the *TP53* pathway.¹⁷⁰ *TP53* regulates the maturation process of miRNAs including miR-16 and miR-143. The presence of sequence variants in miRNA genes may influence their processing, expression, and binding to target mRNAs. A single miRNA may have many mRNAs as targets, and therefore variations in miRNAs may affect their expression which, in turn, could affect the respective

target mRNAs.¹⁷¹ There is increasing evidence that altered microRNA expression is associated with tumor progression and survival in cancer patients. Several studies have analyzed the role of miRNAs as prognostic markers in NSCLC patients.¹⁷² In one study, NSCLC patients were divided into three groups according to expression levels of miR-16, and it was shown that patients with normal levels had the best outcome while those with high levels had the worst outcome. Disease-free survival was 22 months for patients with high levels, 72 months for those with normal levels, and 56 months for those with low levels. The overall survival was 24 months for patients with high levels, 98 months for those with normal levels, and 64 months for those with low levels. The authors concluded that high miR-16 levels may be an independent prognostic factor for poor disease-free survival for NSCLC. Another investigation by Saito et al found that increased levels of miR-21, miR-17, and miR-155 were associated with worse cancer death in cohorts of stage I adenocarcinoma patients from Maryland in the United States, and in Norway and Japan.¹⁷³ The authors highlight the importance of miR-21 as a target for therapy or a biomarker for early-stage prognosis in adenocarcinoma of the lung. In yet another study, it was found that expression of miR-146b, miR-221, let-7a, miR-155, miR-17–5p, miR-27a, and miR-106a was significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased. The expression profiles of miRNAs showed considerable differences between African-American and European Americans.¹⁷⁴ Furthermore, it was found that reduced plasma expression of let-7b was modestly associated with worse cancer-specific mortality in all patients and reduced serum expression of miR-223 was modestly associated with cancer-specific mortality in stage




Figure 3 Overview of interaction of genes from diverse genetic pathways with environmental/occupational factors in lung cancer development. A number of genetic factors such as normal genetic variations in the genome will interact with environmental and/or occupational factors to modulate lung cancer susceptibility, survival, and therapy.

IA/B patients. The authors indicate that expression of let-7b may be associated with prognosis in NSCLC. This study did not find any relationship between miRNA expression and response to adjuvant cisplatin-based chemotherapy.

Conclusion and perspectives

Lung cancer has been considered a disease related to lifestyle and environmental factors. However, recent molecular epidemiological studies have identified normal genetic variations in population that may modify the carcinogenic effect of environmental and lifestyle carcinogens. It is also evident from available data that these genetic variations may affect prognosis and possibly treatment outcomes in lung cancer patients (Figure 3). Studies are still needed to replicate, validate, and test functionally the biological role of polymorphisms associated with risk,¹⁷⁵ prognosis, and therapy.¹⁷⁵ Additionally, two other types of variations known as copy number variations and epigenetic variation affect expression of the genes and we have not reviewed these variations here.^{177,178} These variations are currently being investigated in relation to susceptibility, prognosis, and therapy in lung cancer and there are no conclusive results yet. Studies are also warranted to test the combined effects of both genetic and epigenetic variations. Future large validation studies are needed on the impact of functional SNPs on survival and in therapy. It is also important to address genetic biomarkers coming out of genome-wide association studies which may be beneficial in the future.^{179,180} Historical molecular epidemiological studies on genetic susceptibility will also have to address and adapt to the changing staging criteria over time.¹⁸¹

In conclusion, detection of functional SNPs in metabolic pathways which are associated with increased risk for lung cancer are important, being candidate markers for early diagnostics, hence early treatment and increased likelihood of longer survival. SNPs are also candidate markers for poor prognosis allowing identification of individuals in need for more aggressive therapy. Finally SNPs may help in choosing the most sensitive treatment and for reducing the risk of toxic side effects from chemotherapy and radiotherapy.

Acknowledgment

The financial support of the Norwegian Cancer Society is acknowledged.

Disclosure

The authors report no conflicts of interest in this work.

References

1. International Agency for Research on Cancer. GLOBOCAN 2008: The GLOBOCAN Project [website on the Internet]. Lyon: International Agency for Research on Cancer; 2010. Available from: <http://globocan.iarc.fr/>. Accessed December 19, 2011.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA Cancer J Clin*. 2011;61(4):212–236.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. *CA Cancer J Clin*. 2011;61(2):69–90.
4. Parkin DM. The role of cancer registries in cancer control. *Int J Clin Oncol*. 2008;13(2):102–111.
5. Parkin DM, Ferlay J, Curado MP, et al. Fifty years of cancer incidence: CI5 I-IX. *Int J Cancer*. 2010;127(12):2918–2927.
6. Brennan P, Hainaut P, Boffetta P. Genetics of lung-cancer susceptibility. *Lancet Oncol*. 2011;12(4):399–408.
7. Christiani DC. The environment and the lung: detection, prevention, and mechanism of disease. *Proc Am Thorac Soc*. 2010;7(2):146–148.
8. Sugimura H, Tao H, Suzuki M, et al. Genetic susceptibility to lung cancer. *Front Biosci (Schol Ed)*. 2011;3:1463–1477.
9. Peters S, Kromhout H, Olsson AC, et al. Occupational exposure to organic dust increases lung cancer risk in the general population. *Thorax*. August 19, 2011. [Epub ahead of print.]
10. Sim SC, Ingelman-Sundberg M. The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects. *Hum Genomics*. 2010;4(4):278–281.
11. Sim SC, Altman RB, Ingelman-Sundberg M. Databases in the area of pharmacogenetics. *Hum Mutat*. 2011;32(5):526–531.
12. Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology – with emphasis on cytochrome P450. *Toxicol Sci*. 2011;120(1):1–13.
13. Zhong Y, Carmella SG, Upadhyaya P, et al. Immediate consequences of cigarette smoking: rapid formation of polycyclic aromatic hydrocarbon diol epoxides. *Chem Res Toxicol*. 2011;24(2):246–252.
14. Pratt MM, John K, Maclean AB, et al. Polycyclic aromatic hydrocarbon (PAH) exposure and DNA adduct semi-quantitation in archived human tissues. *Int J Environ Res Public Health*. 2011;8(7):2675–2691.
15. Kim JS, Park JY, Chung WY, et al. Polymorphisms in genes coding for enzymes metabolizing smoking-derived substances and the risk of periodontitis. *J Clin Periodontol*. 2004;31(11):959–964.
16. Smith LE, Denissenko MF, Bennett WP, et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. *J Natl Cancer Inst*. 2000;92(10):803–811.
17. Mollerup S, Berge G, Baera R, et al. Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. *Int J Cancer*. 2006;119(4):741–744.
18. Gasperino J. Gender is a risk factor for lung cancer. *Med Hypotheses*. 2011;76(3):328–331.
19. Uppstad H, Osnes GH, Cole KJ, et al. Sex differences in susceptibility to PAHs is an intrinsic property of human lung adenocarcinoma cells. *Lung Cancer*. 2011;71(3):264–270.
20. Piipari R, Savela K, Nurminen T, et al. Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. *Int J Cancer*. 2000;86(5):610–616.
21. Smith TJ, Guo Z, Guengerich FP, Yang CS. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by human cytochrome P450 1A2 and its inhibition by phenethyl isothiocyanate. *Carcinogenesis*. 1996;17(4):809–813.
22. Bloom J, Hinrichs AL, Wang JC, et al. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans. *Pharmacogenet Genomics*. 2011;21(7):403–416.
23. Bartsch H, Rojas M, Alexandrov K, et al. Metabolic polymorphism affecting DNA binding and excretion of carcinogens in humans. *Pharmacogenetics*. 1995;5 Spec No:S84–S90.

24. Bartsch H, Nair U, Risch A, et al. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. *Cancer Epidemiol Biomarkers Prev*. 2000;9(1):3–28.
25. Chen Z, Li Z, Niu X, et al. The effect of CYP1A1 polymorphisms on the risk of lung cancer: a global meta-analysis based on 71 case-control studies. *Mutagenesis*. 2011;26(3):437–446.
26. Zienolddiny S, Skaug V, Landvik NE, et al. The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung. *Carcinogenesis*. 2009;30(8):1368–1371.
27. Xun WW, Brennan P, Tjonneland A, et al. Single-nucleotide polymorphisms (5p15.33, 15q25.1, 6p22.1, 6q27 and 7p15.3) and lung cancer survival in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Mutagenesis*. 2011;26(5):657–666.
28. Chen B, Qiu LX, Li Y, et al. The CYP1B1 Leu432Val polymorphism contributes to lung cancer risk: evidence from 6501 subjects. *Lung Cancer*. 2010;70(3):247–252.
29. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. *Cancer Res*. 2000;60(13):3440–3444.
30. Helmig S, Seelinger JU, Philipp-Gehlhaar M, Dohrel J, Schneider J. Cyp1B1 mRNA expression in correlation to cotinine levels with respect to the Cyp1B1 L432V gene polymorphism. *Eur J Epidemiol*. 2010;25(12):867–873.
31. Helmig S, Seelinger JU, Dohrel J, Schneider J. RNA expressions of AHR, ARNT and CYP1B1 are influenced by AHR Arg554 Lys polymorphism. *Mol Genet Metab*. 2011;104(1–2):180–184.
32. Laroche-Clary A, Le Morvan V, Yamori T, Robert J. Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vitro models. *Mol Cancer Ther*. 2010;9(12):3315–3321.
33. Ada AO, Kunak C, Hancer F, et al. CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients. *Neoplasma*. 2010;57(6):512–521.
34. Brigelius-Flohe R, Kipp A. Glutathione peroxidases in different stages of carcinogenesis. *Biochim Biophys Acta*. 2009;1790(11):1555–1568.
35. Agundez JA. Polymorphisms of human N-acetyltransferases and cancer risk. *Curr Drug Metab*. 2008;9(6):520–531.
36. Zienolddiny S, Campa D, Lind H, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. *Carcinogenesis*. 2008;29(6):1164–1169.
37. McKay JD, Hashibe M, Hung RJ, et al. Sequence variants of NAT1 and NAT2 and other xenometabolic genes and risk of lung and aerodigestive tract cancers in Central Europe. *Cancer Epidemiol Biomarkers Prev*. 2008;17(1):141–147.
38. Boccia S, Boffetta P, Brennan P, et al. Meta-analyses of the methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and risk of head and neck and lung cancer. *Cancer Lett*. 2009;273(1):55–61.
39. Mao R, Fan Y, Jin Y, Bai J, Fu S. Methylenetetrahydrofolate reductase gene polymorphisms and lung cancer: a meta-analysis. *J Hum Genet*. 2008;53(4):340–348.
40. Tilak AR, Kumar S, Jain M, et al. Association of functionally important polymorphism of microsomal epoxide hydrolase gene (EPHX1) with lung cancer susceptibility. *Cancer Invest*. 2011;29(6):411–418.
41. Lee J, Dahl M, Nordestgaard BG. Genetically lowered microsomal epoxide hydrolase activity and tobacco-related cancer in 47,000 individuals. *Cancer Epidemiol Biomarkers Prev*. 2011;20(8):1673–1682.
42. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. *Epidemiology*. 2006;17(1):89–99.
43. Ataian Y, Krebs JE. Five repair pathways in one context: chromatin modification during DNA repair. *Biochem Cell Biol*. 2006;84(4):490–504.
44. Mannuss A, Trapp O, Puchta H. Gene regulation in response to DNA damage. *Biochim Biophys Acta*. August 16, 2011. [Epub ahead of print.]
45. Shen H, Spitz MR, Qiao Y, et al. Smoking, DNA repair capacity and risk of nonsmall cell lung cancer. *Int J Cancer*. 2003;107(1):84–88.
46. Rouillon C, White MF. The evolution and mechanisms of nucleotide excision repair proteins. *Res Microbiol*. 2011;162(1):19–26.
47. Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. *Int J Med Sci*. 2007;4(2):59–71.
48. Kiyohara C, Takayama K, Nakanishi Y. Lung cancer risk and genetic polymorphisms in DNA repair pathways: a meta-analysis. *J Nucleic Acids*. 2010;2010:701760.
49. Mladenov E, Iliakis G. Induction and repair of DNA double strand breaks: the increasing spectrum of non-homologous end joining pathways. *Mutat Res*. 2011;711(1–2):61–72.
50. Hiom K. Coping with DNA double strand breaks. *DNA Repair (Amst)*. 2010;9(12):1256–1263.
51. Kryston TB, Georgiev AB, Pissis P, Georgakilas AG. Role of oxidative stress and DNA damage in human carcinogenesis. *Mutat Res*. 2011;711(1–2):193–201.
52. Robertson AB, Klungland A, Rognes T, Leiros I. DNA repair in mammalian cells: Base excision repair: the long and short of it. *Cell Mol Life Sci*. 2009;66(6):981–993.
53. Klungland A, Bjelland S. Oxidative damage to purines in DNA: role of mammalian Ogg1. *DNA Repair (Amst)*. 2007;6(4):481–488.
54. Svalir D, Goellner EM, Almeida KH, Sobol RW. Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. *Antioxid Redox Signal*. 2011;14(12):2491–2507.
55. Vens C, Begg AC. Targeting base excision repair as a sensitization strategy in radiotherapy. *Semin Radiat Oncol*. 2010;20(4):241–249.
56. Christmann M, Verbeek B, Roos WP, Kaina B. O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry. *Biochim Biophys Acta*. 2011;1816(2):179–190.
57. Jha P, Suri V, Jain A, et al. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment. *Neurosurgery*. 2010;67(6):1681–1691.
58. Vineis P, Manuguerra M, Kavvoura FK, et al. A field synopsis on low-penetrance variants in DNA repair genes and cancer susceptibility. *J Natl Cancer Inst*. 2009;101(1):24–36.
59. Ricceri F, Matullo G, Vineis P. Is there evidence of involvement of DNA repair polymorphisms in human cancer? *Mutat Res*. August 12, 2011. [Epub ahead of print.]
60. Olausson KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. *N Engl J Med*. 2006;355(10):983–991.
61. Yu H, Zhao H, Wang LE, et al. An analysis of single nucleotide polymorphisms of 125 DNA repair genes in the Texas genome-wide association study of lung cancer with a replication for the XRCC4 SNPs. *DNA Repair (Amst)*. 2011;10(4):398–407.
62. Christiani DC. ERCC2/XPD polymorphisms and lung cancer risk. *J Thorac Oncol*. 2011;6(1):233–235.
63. Hung RJ, Hall J, Brennan P, Boffetta P. Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. *Am J Epidemiol*. 2005;162(10):925–942.
64. Zienolddiny S, Campa D, Lind H, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. *Carcinogenesis*. 2006;27(3):560–567.
65. Park SY, Kim YM, Pyo H. Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated. *Mol Cancer*. 2010;9:222.
66. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. *Nat Rev Cancer*. 2009;9(10):749–758.

67. Bond GL, Hirshfield KM, Kirchhoff T, et al. MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. *Cancer Res.* 2006;66(10):5104–5110.
68. Mogi A, Kuwano H. TP53 mutations in nonsmall cell lung cancer. *J Biomed Biotechnol.* 2011;2011:583929.
69. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. *Curr Cancer Drug Targets.* 2005;5(1):3–8.
70. Eymen B, Gazzeri S, Brambilla C, Brambilla E. Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. *Oncogene.* 2002;21(17):2750–2761.
71. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans. *Oncogene.* 2007;26(9):1317–1323.
72. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. *Cell.* 2004;119(5):591–602.
73. Lind H, Ekstrom PO, Ryberg D, et al. Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer. *Cancer Epidemiol Biomarkers Prev.* 2007;16(10):2077–2081.
74. Siddique M, Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. *Oncogene.* 2006;25(25):3489–3500.
75. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. *Int J Cancer.* 2006;119(3):718–721.
76. Hu Z, Ma H, Lu D, et al. Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. *Int J Cancer.* 2006;118(5):1275–1278.
77. Pine SR, Mechanic LE, Bowman ED, et al. MDM2 SNP309 and SNP354 are not associated with lung cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2006;15(8):1559–1561.
78. Wilkening S, Bermejo JL, Hemminki K. MDM2 SNP309 and cancer risk: a combined analysis. *Carcinogenesis.* 2007;28(11):2262–2267.
79. Wo X, Han D, Sun H, et al. MDM2 SNP309 contributes to tumor susceptibility: A meta-analysis. *J Genet Genomics.* 2011;38(8):341–350.
80. Grochola LF, Zeron-Medina J, Meriaux S, Bond GL. Single-nucleotide polymorphisms in the p53 signaling pathway. *Cold Spring Harb Perspect Biol.* 2010;2(5):a001032.
81. Dong J, Ren B, Hu Z, et al. MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese. *Mol Carcinog.* 2011;50(6):433–438.
82. Vikhanskaya F, Siddique MM, Kei LM, Broggin M, Sabapathy K. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. *Clin Cancer Res.* 2005;11(12):4348–4356.
83. Son JW, Kang HK, Chae MH, et al. Polymorphisms in the caspase-8 gene and the risk of lung cancer. *Cancer Genet Cytogenet.* 2006;169(2):121–127.
84. Zienolddiny S, Martinsen K, Skaug V, Ekstrom PO, Haugen A. The caspase-8 insertion/deletion polymorphism and risk of non-small cell lung cancer. *Am J Biomed Sci.* 2010;2:121–128.
85. Balkwill F, Coussens LM. Cancer: an inflammatory link. *Nature.* 2004;431(7007):405–406.
86. Coussens LM, Werb Z. Inflammation and cancer. *Nature.* 2002;420(6917):860–867.
87. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. *PLoS One.* 2011;6(3):e17479.
88. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. *J Natl Cancer Inst.* 2011;103(14):1112–1122.
89. Bi N, Yang M, Zhang L, et al. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. *Clin Cancer Res.* 2010;16(8):2383–2390.
90. Wu YC, Su LJ, Wang HW, et al. Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer. *J Thorac Oncol.* 2010;5(8):1167–1174.
91. Kim SJ, Rabbani ZN, Dong F, et al. Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. *Med Oncol.* 2010;27(1):91–97.
92. Li F, Liu Y, Chen H, et al. EGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical features. *J Exp Clin Cancer Res.* 2011;30:27.
93. Elrod HA, Yue P, Khuri FR, Sun SY. Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism. *Mol Cancer Ther.* 2009;8(9):2575–2585.
94. Fontaine E, McShane J, Page R, et al. Aspirin and non-small cell lung cancer resections: effect on long-term survival. *Eur J Cardiothorac Surg.* 2010;38(1):21–26.
95. Pal SK, Figlin RA, Reckamp K. Targeted therapies for non-small cell lung cancer: an evolving landscape. *Mol Cancer Ther.* 2010;9(7):1931–1944.
96. Ju R, Wu D, Guo L, et al. Inhibition of pro-inflammatory cytokines in tumour associated macrophages is a potential anti-cancer mechanism of carboxamidotriazole. *Eur J Cancer.* July 16, 2011. [Epub ahead of print.]
97. Campa D, Zienolddiny S, Maggini V, et al. Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. *Carcinogenesis.* 2004;25(2):229–235.
98. Engels EA, Wu X, Gu J, et al. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. *Cancer Res.* 2007;67(13):6520–6527.
99. Lind H, Zienolddiny S, Ryberg D, et al. Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. *Lung Cancer.* 2005;50(3):285–290.
100. Zienolddiny S, Ryberg D, Maggini V, et al. Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. *Int J Cancer.* 2004;109(3):353–356.
101. Landvik NE, Hart K, Skaug V, et al. A specific interleukin-1B haplotype correlates with high levels of IL1B mRNA in the lung and increased risk of non-small cell lung cancer. *Carcinogenesis.* 2009;30(7):1186–1192.
102. Lind H, Haugen A, Zienolddiny S. Differential binding of proteins to the IL1B -31 T/C polymorphism in lung epithelial cells. *Cytokine.* 2007;38(1):43–48.
103. Hart K, Haugen A, Zienolddiny S. Allele-specific induction of IL1B-31T/C promoter polymorphism by lung carcinogens. *Mutat Res.* 2008;656(1–2):14–18.
104. van den Borst B, Souren NY, Gielen M, et al. Association between the IL6-174G/C SNP and maximally attained lung function. *Thorax.* 2011;66(2):179–180.
105. He JQ, Foreman MG, Shumansky K, et al. Associations of IL6 polymorphisms with lung function decline and COPD. *Thorax.* 2009;64(8):698–704.
106. Gao LB, Pan XM, Jia J, et al. IL-8 -251 A/T polymorphism is associated with decreased cancer risk among population-based studies: evidence from a meta-analysis. *Eur J Cancer.* 2010;46(8):1333–1343.
107. Hull J, Ackerman H, Isles K, et al. Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus. *Am J Hum Genet.* 2001;69(2):413–419.
108. Mekinian A, Tamouza R, Pavy S, et al. Functional study of TNF-alpha promoter polymorphisms: literature review and meta-analysis. *Eur Cytokine Netw.* 2011;22(2):88–102.
109. Wei S, Niu J, Zhao H, et al. Association of a novel functional promoter variant (rs2075533 C > T) in the apoptosis gene TNFSF8 with risk of lung cancer – a finding from Texas lung cancer genome-wide association study. *Carcinogenesis.* 2011;32(4):507–515.
110. Hart K, Landvik NE, Lind H, et al. A combination of functional polymorphisms in the CASP8, MMP1, IL10 and SEPS1 genes affects risk of non-small cell lung cancer. *Lung Cancer.* 2011;71(2):123–129.

111. Vogel U, Christensen J, Wallin H, et al. Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. *Mutat Res*. 2008;639(1–2):89–100.
112. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. *Nature*. 2008;452(7187):633–637.
113. McKay JD, Hung RJ, Gaborieau V, et al. Lung cancer susceptibility locus at 5p15.33. *Nat Genet*. 2008;40(12):1404–1406.
114. Tournier JM, Birembaut P. Nicotinic acetylcholine receptors and predisposition to lung cancer. *Curr Opin Oncol*. 2011;23(1):83–87.
115. Sarginson JE, Killen JD, Lazzaroni LC, et al. Markers in the 15q24 nicotinic receptor subunit gene cluster (CHRNA5-A3-B4) predict severity of nicotine addiction and response to smoking cessation therapy. *Am J Med Genet B Neuropsychiatr Genet*. 2011;156B(3):275–284.
116. Kaur-Knudsen D, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Nicotinic acetylcholine receptor polymorphism, smoking behavior, and tobacco-related cancer and lung and cardiovascular diseases: a cohort study. *J Clin Oncol*. 2011;29(21):2875–2882.
117. Yamamoto K, Okamoto A, Isonishi S, Ochiai K, Ohtake Y. A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. *Biochem Biophys Res Commun*. 2001;280(4):1148–1154.
118. Senogles SE. D2 dopamine receptor mediates phospholipase D and antiproliferation. *Mol Cell Endocrinol*. 2003;209(1–2):61–69.
119. Senogles SE. D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69. *Anticancer Drugs*. 2007;18(7):801–807.
120. Campa D, Zienoldddy S, Lind H, et al. Polymorphisms of dopamine receptor/transporter genes and risk of non-small cell lung cancer. *Lung Cancer*. 2007;56(1):17–23.
121. Howlader N, Ries LA, Mariotto AB, et al. Improved estimates of cancer-specific survival rates from population-based data. *J Natl Cancer Inst*. 2010;102(20):1584–1598.
122. Brooks DR, Klint A, Dickman PW, Stahle E, Lambe M. Temporal trends in non-small cell lung cancer survival in Sweden. *Br J Cancer*. 2007;96(3):519–522.
123. Berrino F, De Angelis R, Sant M, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: results of the EURO CARE-4 study. *Lancet Oncol*. 2007;8(9):773–783.
124. Storm HH, Engholm G, Hakulinen T, et al. Survival of patients diagnosed with cancer in the Nordic countries up to 1999–2003 followed to the end of 2006. A critical overview of the results. *Acta Oncol*. 2010;49(5):532–544.
125. Agarwal M, Brahmamday G, Chmielewski GW, Welsh RJ, Ravikrishnan KP. Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. *Lung Cancer*. 2010;68(3):398–402.
126. Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. *J Thorac Oncol*. 2009;4(7):792–801.
127. Leon-Atance P, Moreno-Mata N, Gonzalez-Aragoneses F, et al. Multicenter analysis of survival and prognostic factors in pathologic stage I non-small-cell lung cancer according to the new 2009 TNM classification. *Arch Bronconeumol*. 2011;47(9):441–446.
128. Serrano-Olvera A, Gerson R. Age associated survival rate in non small cell lung cancer. *Gac Med Mex*. 2009;145(1):27–35. Spanish.
129. Veen EJ, Janssen-Heijnen ML, Ritchie ED, et al. Pneumectomy for bronchogenic carcinoma: analysis of factors predicting short- and long-term outcome. *Interact Cardiovasc Thorac Surg*. 2009;9(2):260–264.
130. Palma DA, Tyldesley S, Sheehan F, et al. Stage I non-small cell lung cancer (NSCLC) in patients aged 75 years and older: does age determine survival after radical treatment? *J Thorac Oncol*. 2010;5(6):818–824.
131. Sigel K, Bonomi M, Packer S, Wisnivesky J. Effect of age on survival of clinical stage I non-small-cell lung cancer. *Ann Surg Oncol*. 2009;16(7):1912–1917.
132. Visbal AL, Williams BA, Nichols FC III, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. *Ann Thorac Surg*. 2004;78(1):209–215.
133. Ringer G, Smith JM, Engel AM, Hendy MP, Lang J. Influence of sex on lung cancer histology, stage, and survival in a midwestern United States tumor registry. *Clin Lung Cancer*. 2005;7(3):180–182.
134. Moore R, Doherty D, Chamberlain R, Khuri F. Sex differences in survival in non-small cell lung cancer patients 1974–1998. *Acta Oncol*. 2004;43(1):57–64.
135. Jubelirer SJ, Varela NL, Welch CA, Emmett MK. Does sex make a difference in survival of patients undergoing resection for early stage non-small cell lung cancer (NSCLC)? *WV Med J*. 2009;105(4):18–22.
136. Neal DE. PSA testing for prostate cancer improves survival – but can we do better? *Lancet Oncol*. 2010;11(8):702–703.
137. Horgan AM, Yang B, Azad AK, et al. Pharmacogenetic and germline prognostic markers of lung cancer. *J Thorac Oncol*. 2011;6(2):296–304.
138. Ada AO, Suzen SH, Iscan M. Polymorphisms of cytochrome P450 1A1, glutathione S-transferases M1 and T1 in a Turkish population. *Toxicol Lett*. 2004;151(1):311–315.
139. Goto I, Yoneda S, Yamamoto M, Kawajiri K. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. *Cancer Res*. 1996;56(16):3725–3730.
140. Jin Y, Xu H, Zhang C, et al. Combined effects of cigarette smoking, gene polymorphisms and methylations of tumor suppressor genes on non small cell lung cancer: a hospital-based case-control study in China. *BMC Cancer*. 2010;10:422.
141. Nie Q, Yang XN, An SJ, et al. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA) n polymorphism. *Eur J Cancer*. 2011;47(13):1962–1970.
142. Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN. CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer. *Acta Oncol*. 2007;46(3):361–366.
143. Wei SZ, Zhan P, Shi MQ, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. *Med Oncol*. 2011;28(1):315–321.
144. Ren S, Zhou S, Wu F, et al. Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. *Lung Cancer*. June 13, 2011. [Epub ahead of print.]
145. Park SY, Hong YC, Kim JH, et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. *Med Oncol*. 2006;23(4):489–498.
146. Okuda K, Sasaki H, Hikosaka Y, et al. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. *J Surg Res*. 2011;168(2):206–212.
147. Takenaka T, Yano T, Kiyohara C, et al. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. *Lung Cancer*. 2010;67(1):101–107.
148. Quintela-Fandino M, Hitt R, Medina PP, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. *J Clin Oncol*. 2006;24(26):4333–4339.

149. Kalikaki A, Kanaki M, Vassalou H, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. *Clin Lung Cancer*. 2009;10(2):118–123.
150. Yu DK, Zhang XM, Liu J, et al. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. *Clin Cancer Res*. 2008;14(9):2878–2886.
151. Han JY, Yoon KA, Park JH, et al. DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma. *Cancer*. 2011;117(14):3201–3208.
152. Nogueira A, Catarino R, Coelho A, et al. Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy. *Cancer Chemother Pharmacol*. 2010;66(3):501–506.
153. Jaremko M, Justenhoven C, Schroth W, et al. Polymorphism of the DNA repair enzyme XRCC1 is associated with treatment prediction in anthracycline and cyclophosphamide/methotrexate/5-fluorouracil-based chemotherapy of patients with primary invasive breast cancer. *Pharmacogenet Genomics*. 2007;17(7):529–538.
154. Ahrendt SA, Hu Y, Buta M, et al. p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study. *J Natl Cancer Inst*. 2003;95(13):961–970.
155. Boldrini L, Gisfredi S, Ursino S, et al. Prognostic impact of p53 Pro72 homozygous genotype in non-small cell lung cancer patients. *Oncol Rep*. 2008;19(3):771–773.
156. Chien WC, Wong RH, Cheng YW, Chen CY, Lee H. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors. *Ann Surg Oncol*. 2010;17(4):1194–1202.
157. Chua HW, Ng D, Choo S, et al. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. *BMC Cancer*. 2010;10:88.
158. Liu L, Wu C, Wang Y, et al. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. *J Thorac Oncol*. 2011;6(11):1793–1800.
159. Shih CM, Lin PT, Wang HC, Huang WC, Wang YC. Lack of evidence of association of p21(WAF1/CIP1) polymorphism with lung cancer susceptibility and prognosis in Taiwan. *Jpn J Cancer Res*. 2000;91(1):9–15.
160. Andjelkovic T, Bankovic J, Stojsic J, et al. Coalterations of p53 and PTEN tumor suppressor genes in non-small cell lung carcinoma patients. *Transl Res*. 2011;157(1):19–28.
161. Landi L, Cappuzzo F. Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR. *Nat Rev Clin Oncol*. 2011;8(10):571–573.
162. Dong J, Dai JC, Shu YQ, et al. Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. *Carcinogenesis*. 2010;31(6):1080–1086.
163. Sasaki H, Okuda K, Takada M, et al. A novel EGFR mutation D1012H and polymorphism at exon 25 in Japanese lung cancer. *J Cancer Res Clin Oncol*. 2008;134(12):1371–1376.
164. Giovannetti E, Zucali PA, Peters GJ, et al. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. *Mol Cancer Ther*. 2010;9(3):581–593.
165. Liu G, Gurubhagavatula S, Zhou W, et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib. *Pharmacogenomics J*. 2008;8(2):129–138.
166. Minamiya Y, Miura M, Hinai Y, et al. The CRP 1846T/T genotype is associated with a poor prognosis in patients with non-small cell lung cancer. *Tumour Biol*. 2010;31(6):673–679.
167. Pankratz VS, Sun Z, Aakre J, et al. Systematic evaluation of genetic variants in three biological pathways on patient survival in low-stage non-small cell lung cancer. *J Thorac Oncol*. 2011;6(9):1488–1495.
168. Pine SR, Mechanic LE, Ambs S, et al. Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene. *J Natl Cancer Inst*. 2007;99(18):1401–1409.
169. Hildebrandt MA, Komaki R, Liao Z, et al. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. *PLoS One*. 2010;5(8):e12402.
170. Schetter AJ, Heegaard NH, Harris CC. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. *Carcinogenesis*. 2010;31(1):37–49.
171. Vinci S, Gelmini S, Pratesi N, et al. Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers. *Clin Chem Lab Med*. September 9, 2011. [Epub ahead of print.]
172. Navarro A, Diaz T, Gallardo E, et al. Prognostic implications of miR-16 expression levels in resected non-small-cell lung cancer. *J Surg Oncol*. 2010;103(5):411–415.
173. Saito M, Schetter AJ, Mollerup S, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. *Clin Cancer Res*. 2011;17(7):1875–1882.
174. Heegaard NH, Schetter AJ, Welsh JA, et al. Circulating microRNA expression profiles in early stage non-small cell lung cancer. *Int J Cancer*. May 4, 2011. [Epub ahead of print.]
175. Valachis A, Mauri D, Neophytou C, et al. Translational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not? *Int J Med Sci*. 2011;8(6):492–500.
176. Stewart DJ. Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. *Crit Rev Oncol Hematol*. 2010;5(3):173–234.
177. Risch A, Plass C. Lung cancer epigenetics and genetics. *Int J Cancer*. 2008;123(1):1–7.
178. He Y, Hoskins JM, Mcleod HL. Copy number variants in pharmacogenetic genes. *Trends Mol Med*. 2011;17(5):244–251.
179. Yang P, Li Y, Jiang R, et al. A rigorous and comprehensive validation: common genetic variations and lung cancer. *Cancer Epidemiol Biomarkers Prev*. 2010;19(1):240–244.
180. Huang YT, Heist RS, Chirieac LR, et al. Genome-wide analysis of survival in early-stage non-small-cell lung cancer. *J Clin Oncol*. 2009;27(16):2660–2667.
181. Russell PA, Wainer Z, Wright GM, et al. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification. *J Thorac Oncol*. 2011;6(9):1496–1504.

Lung Cancer: Targets and Therapy

Publish your work in this journal

Lung Cancer: Targets and Therapy is an international, peer-reviewed, open access journal focusing on lung cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. Specific topics covered in the journal include:

Submit your manuscript here: <http://www.dovepress.com/lung-cancer-targets-and-therapy-journal>

Epidemiology, detection and screening; Cellular research and biomarkers; Identification of biotargets and agents with novel mechanisms of action; Optimal clinical use of existing anticancer agents, including combination therapies; Radiation and surgery; Palliative care; Patient adherence, quality of life, satisfaction; Health economic evaluations.

Dovepress